Mon travail de thèse s’est focalisé sur l’étude du rôle des miARN comme modulateurs de l’expression des gonadotropines en réponse à un traitement par la GnRH. Dans un premier temps, nous avons étudié les miARN-132 et -212 fortement induits en réponse à la GnRH dans les cellules gonadotropes. Nous démontrons que l’induction de la production de FSH par la GnRH est dépendante de l’activation des miR-132/212 dans les cellules hypophysaires de rat et dans la lignée cellulaire gonadotrope LβT2. Nous montrons à l’aide de cette lignée que l’élévation de miR-132/212 inhibe l’expression de la lysine déacétylase SIRT1, favorisant ainsi l’acétylation inhibitrice d’un répresseur transcriptionnel de la FSH, conduisant donc à l’activation de l’expression de la FSH (Lannes et al, 2015). J’ai ensuite étudié l’action d’un miARN fortement inhibé en réponse à la GnRH, miR-125b. Nous démontrons que miR-125b bloque la signalisation Gαq/11 en réprimant plusieurs effecteurs de cette voie, sans réguler la voie Gαs. Lors de l'exposition à la GnRH, miR-125b est inactivé par transfert d’un groupement méthyle par l’ARN méthyltransférase NSun2, activée par phosphorylation Gαs/PKA-dépendante. Nous observons que l’induction demiR-132 et de la phosphatase PP1α en réponse à la GnRH dépend de la voie Gαq/11 et est induite par l’inactivation de miR-125b. Nous démontrons que NSun2 est une cible de miR-132 et que la phosphorylation de NSun2 est supprimée par la phosphatase PP1α. Des analyses cinétiques nous ont permis de décrypter le mécanisme de désensibilisation à la stimulation GnRH. Lors de la phase d’induction par la GnRH, l’activation de la voie Gαs/PKA inactive miR-125b permettant une levée d’inhibition de la voie Gαq/11 et par là, l’induction des gènes des gonadotropines, de miR-132 et PP1α. L’activation de ces derniers contribue à l’inactivation de NSun2 et à un retour de miR-125b à son état d'équilibre permettant de nouveau l’inhibition de la voie Gαq/11 et donc de l’expression des gonadotropines (Lannes et al, 2016). Notre étude montre pour la première fois le rôle crucial d’une boucle de régulation entre deux miARN dans le mécanisme de la désensibilisation de la réponse à la GnRH. Le caractère ubiquitaire des acteurs de cette boucle de régulation laisse penser qu’elle pourrait jouer un rôle plus général. Les travaux complémentaires effectués montrent que la GnRH induit la sécrétion de plusieurs miARN. In vitro, nous avons démontré que la GnRH provoque une libération calcium-dépendante de miR-125b et de miR-132 dans le milieu extracellulaire par les cellules gonadotropes. In vivo, nous mettons en évidence chez la rate et la femme, une augmentation sérique des miARN-125b et -132 au moment de la décharge ovulante de LH induite par la GnRH. Ces résultats suggèrent que la cellule gonadotrope hypophysaire est capable d’émettre un message original, sous la forme de miARN, dans la circulation sanguine. Mes travaux de thèse éclairent le rôle clé joué par les miARN dans la réponse de la cellule gonadotrope à la stimulation prolongée à la GnRH. Ils mettent en évidence l’effet bloquant d’un seul miARN, miR-125b sur la signalisation liée à la protéine Gαq/11, une voie activée par nombre de récepteurs. Ils révèlent l’existence d’une boucle de régulation responsable de la désensibilisation à la GnRH mais qui pourrait être plus largement répandue. Enfin, la sécrétion des miARN dans la circulation sanguine induite par la GnRH que nous mettons en évidence pour la première fois ouvre des perspectives particulièrement intéressantes sur la nature du signal généré par les cellules gonadotropes et permet d’envisager l’existence de nouveaux tissus cibles. / GnRH is a hypothalamic neurohormone that stimulates synthesis and release of the pituitary gonadotropins, LH and FSH. Mammalian GnRH receptor lacks a C-terminal tail and is thus not submitted to homologous desensitization. Desensitization of gonadotrope cells to sustained exposure to GnRH relies on post-receptor mechanisms operating at different levels of the Gαq/11-mediated signalling pathway. GnRH was shown to modulate the expression of microRNAs (miRNAs), a new class of signalling regulators composed of small single-stranded RNAs that regulate gene expression at a post-transcriptional level. The purpose of my PhD thesis was to investigate the role of miRNAs in contributing to the regulation of gonadotrope cells by GnRH and notably to its desensitization effect. I first demonstrated that a GnRH-induced rise in miR-132 and miR-212 in rat primary pituitary culture cells and in the LβT2 murine gonadotrope cell line was necessary for efficient stimulation of FSH production. We then showed that the miR-132/212-mediated action of GnRH involved a posttranscriptional decrease of SIRT1, a lysine deacetylase. The lower level of SIRT1 allowed an increase in the acetylated form of FOXO1, a transcriptional repressor of Fshb, leading to its exit from the nucleus and to an increase in FSH expression (Lannes et al, 2015). Then, I focussed on the involvement of miR-125b, a miRNA that was strongly inhibited in response to GnRH. We showed that miR-125b blocked the Gαq/11 signalling pathway, through the repression of several effectors of this pathway, without affecting the Gαs signalling pathway. Upon exposure to GnRH, miR-125b was inactivated by methylation on adenosine by the NSun2 RNA methyltransferase. This later enzyme was activated by a Gαs/PKA-dependent phosphorylation. We observed that the induction of miR-132 and PP1α phosphatase in response to GnRH depends on a Gαq/11 activation allowed by the inactivation of miR-125b. We demonstrated that NSun2 is a target of miR-132 and that phosphorylation of NSun2 is suppressed by PP1α. Kinetic analyses enabled us to decipher the desensitization mechanism to GnRH stimulation. During the induction phase, the Gαs/PKA activation led to lower miR-125b levels, allowing Gαq/11 signalling and hence, transcriptional activation of gonadotropins genes. Co-activation of miR-132 and PP1α contributed to the inactivation of NSun2 and a return of miR-125b back to its equilibrium state leading to Gαq/11 signalling inhibition and therefore, to the arrest of gonadotropins expression (Lannes et al, 2016). Our study shows for the first time the crucial role of a miRNAs regulatory loop in the GnRH-induced mechanism of desensitization. The ubiquitous nature of the actors of this regulatory loop suggests that it may play a more general role. Additional works carried out showed that GnRH induces the secretion of several miRNAs. In vitro, we demonstrated that the GnRH causes a calcium-dependent release of miR-125b and miR-132 in the extracellular medium by the gonadotrope cells. In vivo, we highlighted a miRNA-125b and -132 increase in serum at the time of the ovulating LH surge induced by GnRH in rats and women. These results suggest that the pituitary gonadotropic cell is capable of transmitting an original message in the form of miRNA, into the bloodstream. My PhD work unravels the key role played by miRNAs in the gonadotrope cells response to GnRH-sustained stimulation. They highlight the blocking effect of a single miRNA, miR-125b on the Gαq/11 signalling, a pathway activated by many other membrane receptors. They indicate the existence of a regulation loop responsible for the desensitization to GnRH but which could be more widespread. Finally, the secretion of miRNAs in blood flow induced by the GnRH that we show for the first time opens up particularly interesting perspectives on the nature of the signal generated by the gonadotrope cells and allows to consider the existence of new target tissues.

Resveratrol (RSV) is a natural compound that improves mitochondrial function and metabolic health in animal models. Thus far, RSV’s effects on metabolic outcomes in humans are controversial, and RSV’s acute mechanism has not yet been confirmed in vivo. This study aimed to evaluate the effect of an acute dose of RSV on insulin sensitivity and fatty acid oxidation, and to determine RSV’s mechanism of action in human skeletal muscle and adipose tissue. Overweight males (n=8; BMI, 30.5±3.6; VO2peak, 34.0±7.3 ml/kg) reported to the lab on 2 occasions and were provided a breakfast supplemented with 0.3g of RSV or a placebo pill. Experiments were performed in random order using a double blind crossover design. Gas exchange measures, blood samples, and skeletal muscle and adipose tissue biopsies were obtained before and 2 hours after the supplement meal. RSV acutely improved insulin sensitivity, but had no effect on fatty acid oxidation. Additionally, RSV supplementation had no effect on the intracellular signaling of key proteins proposed to mediate its effects in skeletal muscle and adipose tissue. Taken together, these results suggest a single dose of RSV can acutely enhance insulin sensitivity, but its mechanism of action is not conserved across species, and its intracellular signaling pathway is different in humans than previously thought. Due to its insulin sensitizing effect, RSV retains its clinical value, but further research is required to determine its most useful application for human metabolic health. / Thesis (Master, Kinesiology & Health Studies) -- Queen's University, 2013-06-06 13:30:03.522

SirT1 is a class III histone deacetylase that has beneficial roles in various diseases related to aging such as cancer, diabetes and neurodegenerative disease. Resveratrol is a natural compound that mimics most of the beneficial effects attributed to SirT1. Resveratrol has toxicity towards cancer cells and has been reported to be a direct activator of SirT1. Interestingly, SirT1 over-expression has also been reported to be toxic. We set out to determine if resveratrol toxicity is mediated through activation of SirT1. We have assessed resveratrol toxicity in embryonic stem cells and mouse embryonic fibroblast (MEFs) across different SirT1 genotypes. Our data indicates that SirT1 is not implicated in resveratrol toxicity in either normal or transformed MEFs. Thus, resveratrol toxicity does not appear to be mediated by SirT1.

SirT1 is a class III histone deacetylase that has beneficial roles in various diseases related to aging such as cancer, diabetes and neurodegenerative disease. Resveratrol is a natural compound that mimics most of the beneficial effects attributed to SirT1. Resveratrol has toxicity towards cancer cells and has been reported to be a direct activator of SirT1. Interestingly, SirT1 over-expression has also been reported to be toxic. We set out to determine if resveratrol toxicity is mediated through activation of SirT1. We have assessed resveratrol toxicity in embryonic stem cells and mouse embryonic fibroblast (MEFs) across different SirT1 genotypes. Our data indicates that SirT1 is not implicated in resveratrol toxicity in either normal or transformed MEFs. Thus, resveratrol toxicity does not appear to be mediated by SirT1.

Mitochondrial function declines with aging and obesity, and has been implicated in the development of many age-related diseases. Caloric restriction (CR) prevents aging and has been shown to induce mitochondrial biogenesis and improve mitochondrial function. These effects may involve increased activity of the \(NAD^+\)-dependent deacetylase SIRT1. Indeed, overexpression of SIRT1 reproduces many of the health benefits of CR including induction of mitochondrial biogenesis by deacetylation and activation of the transcriptional co-activator \(PGC-1\alpha\). Because mitochondria regulate cellular functions important for aging, including, cellular energy production, ROS generation, and apoptosis, determining why mitochondrial function declines with age will improve our understanding of the underlying forces that drive organismal aging. Resveratrol and other SIRT1 activators induce mitochondrial biogenesis and protect against metabolic decline, but whether SIRT1 mediates these benefits is still a matter of debate. To circumvent the developmental defects of germ-line SIRT1 knockouts, we have developed the first inducible system that permits whole-body deletion of SIRT1 in adult mice. Obese mice treated with a moderate dose of resveratrol showed increased mitochondrial biogenesis and function, AMPK activation, and increased \(NAD^+\) levels in skeletal muscle, whereas SIRT1 knockouts displayed none of these benefits. Overexpression of SIRT1 in mice mimicked these effects, demonstrating that SIRT1 is sufficient and necessary for resveratrol to increase mitochondrial function in obese animals, and indicating a central role for SIRT1 in mediating the benefits of this molecule on muscle. Loss of SIRT1 or aging causes mitochondrial dysfunction and decreased expression of mitochondrial-encoded electron transport chain (ETC) components. This decrease in mitochondrial-encoded, but not nuclear-encoded ETC components in SIRT1 knockouts, which we have termed “genome asynchrony”, is independent of \(PGC-1\alpha\). Elevating \(NAD^+\) levels by treatment with the \(NAD^+\) precursor NMN prevented genome asynchrony and mitochondrial dysfunction in aged animals, similar to effects seen with CR. Together these data demonstrate that SIRT1 plays an essential role in preventing genome asynchrony, and that maintaining \(NAD^+\) levels and SIRT1 activity with age may prevent mitochondrial dysfunction. Since SIRT1 is required for NMN or resveratrol to improve mitochondrial function, compounds that activate SIRT1 or elevate \(NAD^+\) may help treat or prevent age-related diseases caused by mitochondrial dysfunction.

SirT1 is a class III histone deacetylase that has beneficial roles in various diseases related to aging such as cancer, diabetes and neurodegenerative disease. Resveratrol is a natural compound that mimics most of the beneficial effects attributed to SirT1. Resveratrol has toxicity towards cancer cells and has been reported to be a direct activator of SirT1. Interestingly, SirT1 over-expression has also been reported to be toxic. We set out to determine if resveratrol toxicity is mediated through activation of SirT1. We have assessed resveratrol toxicity in embryonic stem cells and mouse embryonic fibroblast (MEFs) across different SirT1 genotypes. Our data indicates that SirT1 is not implicated in resveratrol toxicity in either normal or transformed MEFs. Thus, resveratrol toxicity does not appear to be mediated by SirT1.

Inflammation is a homeostatic response to tissue injury or infection, which is normally short- lived and quickly resolves to limit tissue damage. In contrast, chronic inflammation has been linked to a variety of human diseases, including cancers such as glioblastoma multiforme (GBM). GBMs are very aggressive tumors with very low patient survival rates, which have not improved in several decades. GBM tumors are characterized by necrosis and profound inflammation; with cytokines secreted by both GBM cells and the tumor microenvironment. The mechanisms by which chronic inflammation develops and persists in GBM regardless of multiple anti-inflammatory feedback loops remain elusive. This project identifies a molecular switch which promotes chronic inflammation in GBM, but not primary human astrocytes.

SirT1 is a class III histone deacetylase that has beneficial roles in various diseases related to aging such as cancer, diabetes and neurodegenerative disease. Resveratrol is a natural compound that mimics most of the beneficial effects attributed to SirT1. Resveratrol has toxicity towards cancer cells and has been reported to be a direct activator of SirT1. Interestingly, SirT1 over-expression has also been reported to be toxic. We set out to determine if resveratrol toxicity is mediated through activation of SirT1. We have assessed resveratrol toxicity in embryonic stem cells and mouse embryonic fibroblast (MEFs) across different SirT1 genotypes. Our data indicates that SirT1 is not implicated in resveratrol toxicity in either normal or transformed MEFs. Thus, resveratrol toxicity does not appear to be mediated by SirT1.

Basement of healthy embryo development comes from quality of oocytes and spermatozoa. Today, when percentage of couples suffering infertility together with assisted reproductive therapy (ART) is increasing, understanding to gamete biology and heritable epigenetic code is crucial. The study is focused on promising epigenome based markers that could serve as indicators of gamete quality for either their screening or selection for ART. Accordingly selected markers were used for the investigation of environmental pollutant bisphenol S (BPS) effect on gametes quality. To obtain these aims, we have used human semen samples, boar semen samples and ICR mice gametes. Samples were analyzed by flow cytometry, immunocytochemistry and western blot analysis. All experimental work was in accordance with Ethics committee University Hospital in Pilsen and approved experimental designs for appropriate experimental animal project. In the study, we detected the dimethylation of histone H3 on lysine K4 (H3K4me2) as potential epigenetic marker of sperm quality and chromatin immaturity. Secondly, we observed the role of the gasotransmitter hydrogen sulphide (H2S) as anti-capacitating agents, slowing down capacitation possibly through post-translational modification of proteins. Thirdly, SIRT1 histone deacetylase was...

Metformin has been used clinically since 1957 for its efficacy and safety as therapy for type 2 diabetes. Besides ameliorating hyperglycemia without risk of hypoglycemia, metformin also lowers plasma triglyceride levels. Furthermore, a wealth of data shows that metformin facilitates weight loss in mice as well as humans. Due to its numerous metabolic benefits, researchers and clinicians are interested in the possibility of using metformin as treatment to combat obesity and other metabolic disorders such as non-alcoholic fatty liver disease (NAFLD). Despite being the most commonly prescribed anti-diabetic, metformin’s complete mechanism(s) for weight loss or for lowering glucose and lipids remains an enigma. Our studies show that metformin-treated mice exhibited decreased caloric intake, providing a viable mechanism for metformin to bring about weight loss. Intriguingly, we found that metformin induces PRDM16 to promote browning of iWAT and increase expression of thermogenic genes such as UCP1 and DIO2. However, metformin did not appear to increase energy expenditure. It’s possible that metformin’s effect on energy expenditure was masked since energy expenditure measurements were taken when metformin-treated mice were still losing weight and were in a state of negative energy balance. Recently, there has been much attention given to AMPK activators as exercise mimetics. Metformin is known to activate AMPK and similarly brings about many beneficial effects as exercise such as alleviation of obesity-induced NAFLD. SIRT1 stimulation by resveratrol and delivery of exogenous FGF21 mimics metformin’s ability to combat obesity and improve NAFLD. Collectively, these results implicate metformin, resveratrol, and exogenous administration of FGF21 as beneficial therapies for weight loss and amelioration of NAFLD.